| Literature DB >> 34094984 |
Genya Gorshtein1, Olivia Grafinger2, Marc G Coppolino1.
Abstract
During metastasis, cancer cells can invade extracellular matrix (ECM) through a process mediated by matrix-degrading protrusions of the plasma membrane, termed invadopodia. Formation of invadopodia correlates with cells' invasive and metastatic potential, and thus presents a potential target for therapeutic approaches to target metastatic progression. Invadopodia formation is dependent on the recruitment of proteins involved in intracellular signaling, actin cytoskeleton remodeling, and proteolytic matrix modification. The latter includes matrix degrading enzymes such as MT1-MMP, MMP2, and MMP9. These essential invadopodium-associated enzymes are required for localized matrix degradation, and their localization at invadopodia is central to invadopodium-based cancer cell invasion. Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) facilitate intracellular vesicle traffic, including that involved in the transport of invadopodium-associated proteins, and in so doing promote modification of ECM and modulation of signaling pathways involved in the movement of cancer cells. Specific SNARE complexes have been found to support invadopodia formation, and these complexes are, in turn, regulated by associated proteins that interact specifically with SNAREs. Targeting SNARE regulatory proteins thus provides a possible approach to disrupt SNARE-dependent delivery of invadopodial proteins, including MT1-MMP, to sites of ECM modification. Here, we review recent studies of SNARE regulators that hold potential as targets for the development of anti-metastatic therapies for patients burdened with invadopodia-forming cancer types.Entities:
Keywords: SNARE; invadopodia formation; invasion; membrane type 1–matrix metalloproteinase; vesicle traffic
Year: 2021 PMID: 34094984 PMCID: PMC8177742 DOI: 10.3389/fonc.2021.679955
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1SNARE-mediated vesicle trafficking of invadopodium-associated proteins is essential for invadopodia formation. (A) vesicles containing invadopodial proteins, such as MT1-MMP, EGFR, and MMP2/MMP9, are trafficked to invadopodia pre-cursor sites. (B) As the vesicle comes in proximity to the target membrane, a SNARE complex is formed, involving t-SNAREs (Stx13, SNAP23) and v-SNAREs (VAMP7), that facilitates membrane fusion. (C) Membrane fusion results in the localization of invadopodium-associated proteins, at sites of ECM invasion. Additional invadopodial proteins are trafficked in a similar manner, including β1- containing integrins, which mediate downstream signaling pathways and promote invadopodia-based functions.
Figure 2Proposed model for inhibiting SNARE-mediated membrane trafficking at invadopodia. (A) In normal conditions, components are delivered to invadopodia sites in a SNARE-regulated manner. (1) For example, vesicles containing MT1-MMP, EGFR and the v-SNARE Stx4 are depicted. (2) When the vesicle reaches its destination, a SNARE complex is formed by the v-SNARE and t-SNAREs (e.g. SNAP23, VAMP7) on the target membrane. This SNARE interaction is facilitated by the SNARE regulatory protein, Munc18c, which primes Stx4 for association with its cognate SNARE partners. (3) SNARE-mediated fusion between the vesicle and the invadopodial membrane results in the delivery of proteins necessary for invadopodia formation and cellular invasion. (B) Potential therapeutic targeting of a SNARE regulatory protein inhibitor. (1) As in A, vesicles containing MT1-MMP, EGFR and the v-SNARE Stx4 are depicted. (2) The presence of a Munc18c inhibitor impairs Stx4 involvement in SNARE complex formation, which reduces membrane fusion and delivery of invadopodial proteins leading to decreased invadopodia formation and cell invasion.